Thomas Dubensky
Director/Board Member bij HTG MOLECULAR DIAGNOSTICS, INC.
Vermogen: 443 171 $ op 31-03-2024
Profiel
Thomas W.
Dubensky was the founder of Anza Therapeutics, Inc. (founded in 2007) where he held the title of Chief Scientific Officer in 2010.
He is currently the Director at HTG Molecular Diagnostics, Inc. (since 2022) and the President & Director at TempestTx, Inc. (since 2017).
In his former positions, he was the Scientific Director at Chiron Corp., President & Director at Tempest Therapeutics, Inc. (2017-2023), Vice President at Onyx Pharmaceuticals, Inc., Vice President-Research at Cerus Corp.
(2002-2007), Chief Scientific Officer at Aduro BioTech, Inc. (2011-2017), and Principal at Chiron Viagene, Inc. He also served as the Chief Scientific Officer at Immune Design Corp.
Dr. Dubensky completed his undergraduate degree at the University of California, Berkeley and obtained his doctorate degree from the University of Colorado Health Sciences Center.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 01-03-2023 | 113 343 ( 0.51% ) | 443 171 $ | 31-03-2024 |
Actieve functies van Thomas Dubensky
| Bedrijven | Functie | Begin |
|---|---|---|
| HTG MOLECULAR DIAGNOSTICS, INC. | Director/Board Member | 18-08-2022 |
TempestTx, Inc.
 TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | President | - |
Eerdere bekende functies van Thomas Dubensky
| Bedrijven | Functie | Einde |
|---|---|---|
| TEMPEST THERAPEUTICS, INC. | President | 15-09-2023 |
| CHINOOK THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31-08-2017 |
| CERUS CORPORATION | Chief Tech/Sci/R&D Officer | 16-11-2007 |
Chiron Viagene, Inc.
 Chiron Viagene, Inc. Miscellaneous Commercial ServicesCommercial Services Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million. | Corporate Officer/Principal | - |
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Thomas Dubensky
| University of California, Berkeley | Undergraduate Degree |
| University of Colorado Health Sciences Center | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| CERUS CORPORATION | Health Technology |
| HTG MOLECULAR DIAGNOSTICS, INC. | Commercial Services |
| TEMPEST THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
TempestTx, Inc.
TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Health Technology |
Chiron Viagene, Inc.
Chiron Viagene, Inc. Miscellaneous Commercial ServicesCommercial Services Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million. | Commercial Services |
Anza Therapeutics, Inc.
 Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Anza Therapeutics, Inc. develops products in the fields of cancer and infectious diseases. It also develops immunotherapy for infectious diseases, therapeutic vaccines for treating cancers that over-express Mesothelin and for treating people infected with the hepatitis C virus (HCV). The company was founded in 2007 and is headquartered in Concord, CA. | Health Technology |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
